XtalPi and ReviR Achieve Clinical Milestone with RTX-117 for Neurological Disorders XtalPi's AI-platform achieves a significant milestone with ReviR as they initiate the first clinical trial of RTX-117 for CMT and VWM.

XtalPi and ReviR Achieve Clinical Milestone with RTX-117 for Neurological Disorders #United_States #Cambridge #XtalPi #RTX-117 #ReviR

XtalPi's Automation Solutions Make Major Impact at BASF's Innovation Campus XtalPi has successfully implemented an advanced automated workstation at BASF, revolutionizing the way stability testing is conducted in the chemical industry.

XtalPi's Automation Solutions Make Major Impact at BASF's Innovation Campus #Shanghai #USA #Automation #XtalPi #BASF

Pioneering the Future of Drug Discovery: Insights from XtalPi’s International Symposium XtalPi recently held its 2026 International Symposium, showcasing innovative AI techniques in molecular glue drug discovery, featuring expert insights worldwide.

Pioneering the Future of Drug Discovery: Insights from XtalPi’s International Symposium #China #Shanghai #AI_Drug_Discovery #XtalPi #molecular_glue

Ailux Partners with Lilly to Propel Bispecific Antibody Innovations in Drug Development Ailux, a subsidiary of XtalPi, is collaborating with Eli Lilly to enhance bispecific antibody development using AI technology for novel therapies.

Ailux Partners with Lilly to Propel Bispecific Antibody Innovations in Drug Development #China #Shanghai #Eli_Lilly #XtalPi #Ailux

Ailux Partners with Lilly to Revolutionize Bispecific Antibody Development Ailux, a subsidiary of XtalPi, collaborates with Lilly to enhance bispecific antibody discovery, potentially worth $345 million in total.

Ailux Partners with Lilly to Revolutionize Bispecific Antibody Development #Shanghai #USA #Lilly #XtalPi #Ailux

XtalPi Advances Cancer Treatment with Clinical Trial Approval for PRMT5 Inhibitor PEP08 XtalPi Inc. celebrates a major milestone as its PRMT5 inhibitor PEP08 receives regulatory clearance for Phase 1 clinical trials. This advancement marks a significant step in AI-driven drug discovery.

XtalPi Advances Cancer Treatment with Clinical Trial Approval for PRMT5 Inhibitor PEP08 #China #Shenzhen #XtalPi #PEP08 #PharmaEngine

XtalPi and Dong-A ST: A New Chapter in Immunotherapy and Inflammation Research XtalPi has partnered with Dong-A ST for joint research in immunology and inflammation therapies, utilizing advanced AI technology to enhance drug discovery.

XtalPi and Dong-A ST: A New Chapter in Immunotherapy and Inflammation Research #USA #Cambridge #XtalPi #Immunology #Dong-A_ST

XtalPi and DoveTree Forge a $6 Billion Collaboration to Transform AI in Drug Discovery XtalPi and DoveTree embark on a groundbreaking collaboration valued at $6 billion to revolutionize drug discovery using AI and robotics, focusing on therapies for oncology, immunology, and more.

XtalPi and DoveTree Forge a $6 Billion Collaboration to Transform AI in Drug Discovery #USA #Cambridge #AI_Drug_Discovery #XtalPi #DoveTree

XtalPi and Pfizer Forge Stronger Partnership in AI-Powered Drug Discovery XtalPi and Pfizer have expanded their collaboration to develop a next-gen molecular modeling platform, enhancing AI-driven drug discovery methods.

XtalPi and Pfizer Forge Stronger Partnership in AI-Powered Drug Discovery #USA #Cambridge #AI_Drug_Discovery #Pfizer #XtalPi

XtalPi's Acquisition of Liverpool ChiroChem Transforms Chemical Space Exploration XtalPi's strategic acquisition of Liverpool ChiroChem will revolutionize the field of chemical space exploration, combining AI technology with automated chiral chemistry.

XtalPi's Acquisition of Liverpool ChiroChem Transforms Chemical Space Exploration #United_States #Cambridge #XtalPi #Liverpool_ChiroChem #AI_Chemistry

Funding Raises: #XtalPi HK2.1B Post-IP Equity; #Zolve $51M Series B & $200M Debt; #CelestialAI $250M Series C1; #LilaSciences $200M Seed; #Terabase $130M Series C; #Cybereason $120M Series H; #Turing $111M Series E; #InsilicoMedicine $110M Series E; #Reflection $105M Series A

UCB and XtalPi Collaborate on Advanced AI Solutions for Biologics Discovery UCB collaborates with XtalPi's Ailux Biologics to enhance biologics drug discovery using the innovative XtalFold™ AI platform, transforming therapeutic development.

UCB and XtalPi Collaborate on Advanced AI Solutions for Biologics Discovery #USA #Cambridge #UCB #XtalPi #XtalFold